| 2025-11-18 |
详情>>
内部人交易：
Shah Gaurav等共交易4笔
|
| 2025-11-06 |
详情>>
股本变动：
变动后总股本10822.22万股
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.63美元,归母净利润-1.81亿美元,同比去年增长8.99%
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益-1.18美元,归母净利润-1.3亿美元,同比去年增长1.10%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.56美元,归母净利润-6133.4万美元,同比去年增长1.16%
|
| 2025-04-30 |
股东大会：
将于2025-06-18召开股东大会
会议内容 ▼▲
- 1.The election of ten directors named in the proxy statement to hold office until the Company’s annual meeting of stockholders in 2026, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal;
2.The ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.A non-binding, advisory vote on the compensation of our named executive officers;
4.The transaction of any other business that properly comes before the Annual Meeting or any adjournments and postponements thereof.
|
| 2025-02-27 |
详情>>
业绩披露：
2022年年报每股收益-3.26美元,归母净利润-2.22亿美元,同比去年增长-31.23%
|
| 2025-02-27 |
详情>>
业绩披露：
2024年年报每股收益-2.73美元,归母净利润-2.59亿美元,同比去年增长-5.35%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.11美元,归母净利润-1.98亿美元,同比去年增长-6.71%
|
| 2024-08-06 |
详情>>
业绩披露：
2023年中报每股收益-1.55美元,归母净利润-1.24亿美元,同比去年增长-27.37%
|
| 2024-08-06 |
详情>>
业绩披露：
2024年中报每股收益-1.4美元,归母净利润-1.32亿美元,同比去年增长-6.18%
|
| 2024-06-28 |
复牌提示：
2024-06-28 06:56:37 停牌，复牌日期 2024-06-28 08:00:00
|
| 2024-05-07 |
详情>>
业绩披露：
2024年一季报每股收益-0.66美元,归母净利润-6205.4万美元,同比去年增长-6.38%
|
| 2024-04-29 |
股东大会：
将于2024-06-13召开股东大会
会议内容 ▼▲
- 1.Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2025, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal;
2.Ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.Consider and act upon a non-binding, advisory vote on the compensation of our named executive officers;
4.Approval of an Amendment to our certificate of incorporation to increase the authorized number of shares of common stock from 120,000,000 shares to 180,000,000 shares;
5.Consider any other business properly brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-02-27 |
详情>>
业绩披露：
2023年年报每股收益-2.92美元,归母净利润-2.46亿美元,同比去年增长-10.7%
|
| 2023-11-07 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-2.3美元,归母净利润-1.86亿美元,同比去年增长-19.85%
|
| 2023-04-28 |
股东大会：
将于2023-06-22召开股东大会
会议内容 ▼▲
- 1.Election of the nine (9) directors named in the proxy statement to hold office until the annual meeting of stockholders in 2024, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal.
2.Ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
3.Consider and act upon a non-binding, advisory vote on the compensation of our named executive officers.
4.Consider any other business properly brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2022-04-29 |
股东大会：
将于2022-06-13召开股东大会
会议内容 ▼▲
- 1.to elect nine (9) directors named in the proxy statement to hold office until the Company’s annual meeting of stockholders in 2023, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal;
2.to ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.to consider and act upon a non-binding, advisory vote on the compensation of our named executive officers;
4.to transact any other business that properly comes before the Annual Meeting or any adjournments and postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-09 |
财报披露：
美东时间 2021-08-09 盘后发布财报
|
| 2021-04-30 |
股东大会：
将于2021-06-14召开股东大会
会议内容 ▼▲
- 1.Election of the eight (8) directors named in the proxy statement to hold office until the annual meeting of stockholders in 2022, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal;
2.Ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To consider and act upon a non-binding, advisory vote on the compensation of our named executive officers;
4.To consider and act upon a non-binding, advisory vote on the frequency of future advisory votes on the compensation of our named executive officers;
5.Consideration of any other business properly brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-04-24 |
股东大会：
将于2020-06-16召开股东大会
会议内容 ▼▲
- (1)Election of the eight (8) directors named in the proxy statement to hold office until the annual meeting of stockholders in 2021, or until their respective successors have been duly elected and qualified;
(2)Ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020;
(3)Consideration of a stockholder proposal requesting the implementation of majority voting in uncontested director elections if the stockholder proposal is properly presented for consideration at the Annual Meeting;
(4)Consideration of any other business properly brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2019-04-30 |
股东大会：
将于2019-06-17召开股东大会
会议内容 ▼▲
- 1.to elect seven (7) directors named in the proxy statement to hold office until the Company’s annual meeting of stockholders in 2020, or until their respective successors have been duly elected and qualified;
2.to ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019; 3.to transact any other business that properly comes before the Annual Meeting or any adjournments and postponements thereof.
|
| 2018-04-30 |
股东大会：
将于2018-06-25召开股东大会
会议内容 ▼▲
- (1)Approval of an amendment to Rocket Pharmaceuticals, Inc.’s (the “Company”) Seventh Amended and Restated Certificate of Incorporation to declassify the Board of Directors of the Company (the “Board”);
(2)Approval of an amendment to the Company’s Seventh Amended and Restated Certificate of Incorporation to eliminate the supermajority voting requirement with respect to the removal of directors and replace it with a majority voting standard;
(3)If Proposal 1 to declassify the Board is approved by the stockholders, election of the seven (7) directors named in the proxy statement to hold office until the annual meeting of stockholders in 2019, or until their respective successors have been duly elected and qualified;
(4)If Proposal 1 to declassify the Board is not approved by the stockholders, election of two (2) Class I directors named in the proxy statement to the Board for a term of three (3) years, or until their respective successors have been duly elected and qualified;
(5)Ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018;
(6)Approval of the Company’s Second Amended and Restated 2014 Stock Option and Incentive Plan;
(7)Consideration of any other business properly brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2018-01-05 |
详情>>
拆分方案：
每4.0000合并分成1.0000股
|
| 2017-12-04 |
股东大会：
将于2018-01-04召开股东大会
会议内容 ▼▲
- 1.To approve the issuance of Inotek’s common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated as of September 12, 2017, by and among Inotek, Rome Merger Sub, a wholly-owned subsidiary of Inotek, and Rocket Pharmaceuticals, Ltd., which we refer to as Rocket, and the resulting “change of control” of Inotek under NASDAQ rules.
2.To approve an amendment to Inotek’s seventh amended and restated certificate of incorporation to effect a reverse stock split of Inotek’s common stock.
3.To consider and vote upon an adjournment of the special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals 1 and 2.
|
| 2017-04-26 |
股东大会：
将于2017-06-20召开股东大会
会议内容 ▼▲
- 1.Election of the Class III directors nominated by the Board named in the attached proxy statement as directors to serve on the Board for a three-year term and until his successor has been duly elected and qualified, or until his earlier resignation or removal;
2.Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3.Consideration of any other business properly brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2016-05-06 |
股东大会：
将于2016-06-23召开股东大会
会议内容 ▼▲
- (1)Election of the Class II directors nominated by the Board named in the attached proxy statement as directors to serve on the Board for a three-year term and until his successor has been duly elected and qualified, or until his earlier resignation or removal;
(2)Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
(3)Consideration of any other business properly brought before the Annual Meeting or any adjournment or postponement thereof.
|